Form 4: Amarin Director O'Connor Receives Stock Options and Restricted Stock Units

Director Oliver O'Connor received stock options and restricted stock units (RSUs) from Amarin Pharma following the company's annual general meeting.

Summary

• Oliver O'Connor, a director of Amarin Corp PLC, received stock options and restricted stock units (RSUs) on April 18, 2024.
• The stock options grant is for 179,795 ordinary shares with an exercise price of $0.87 per share.
• These options vest over three years, with 33% vesting on the first anniversary and the remaining balance vesting in equal quarterly installments.
• O'Connor also received 50,287 RSUs, which vest in three equal installments on April 18, 2025, April 18, 2026, and April 18, 2027.
• Each RSU represents a contingent right to receive one ordinary share or cash in lieu thereof at the Issuer's discretion.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices that align director interests with shareholders. The vesting schedules promote long-term commitment.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule of the options and RSUs encourages long-term commitment from the director.

Industry Context

Granting stock options and RSUs to directors is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, particularly in the pharmaceutical sector.
• Companies like Pfizer, Johnson & Johnson, and Novartis also utilize similar equity-based compensation plans for their executives and directors.
• The vesting schedules described are typical, encouraging long-term commitment and alignment with shareholder value.

Stakeholder Impact

• The grant of stock options and RSUs can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates